f 10

VUF10166 is a novel, potent and competitive antagonist for 5-HT3A receptor with Ki of 0.04 nM, its affinity at 5-HT3AB receptor is significantly lower.

10-Bromo-5H-dibenzo[b,f]azepine-5-carboxamide is a useful organic compound for research related to life sciences. The catalog number is T66988 and the CAS number is 59690-97-0.

9-Chloromethyl-10-hydroxy-11-F-Camptothecin, a novel derivative of camptothecin, functions as a DNA topoisomerase I (Topo I) inhibitor with potential applications in anticancer research [1].

Antibiotic PF 1018 is a useful organic compound for research related to life sciences and the catalog number is T126064.

PF 1022A is an N-methylated cyclooctadepsipeptides with strong anthelmintic properties. It also acts as an ionosphere.

UCF 101 is a specific inhibitor of HtrA2 and reduces apoptosis in PC12 cells.

SK&F 103784 is a vasopressin antagonist.

SK&F 107260 is an RGD-containing peptide. It is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

GF 109 is an inhibitor of ACE.

SKF 106760 is used as a glycoprotein IIb IIIa antagonist.

SK&F 104976 is a 32-carboxylic acid derivative of lanosterol. It was found to be a potent lanosterol 14 alpha-demethylase (14 alpha DM) inhibitor.

WF 10129 is a new angiotensin converting enzyme inhibitor generated by a fungus, Doratomyces putredinis.

PF 10040 is an antagonist of platelet activating factor (PAF).

F 107461 is a hydroxyethylene dipeptide isostere.

SK&F 108361 is a symmetric diol that binds HIV-1 protease symmetrically.

Skf 107457 is a hexapeptide substrate analog with the scissile bond being replaced by a hydroxyethylene isostere.

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity. One vial of this peptide may be used as a methyltransferase acceptor peptide for more than 200 reactions at 15 μM.

Antibiotic PF 1052 is a fungal metabolite originally isolated from Phoma.1,2 It is active against S. aureus, S. parvulus, and C. perfringens (MICs = 3.13, 0.78, and 0.39 μg/ml, respectively), among others.1 It inhibits neutrophil migration in a wound assay using zebrafish larvae expressing GFP-labeled neutrophils, reducing pseudopodia formation and inducing rounding of neutrophils.2 Antibiotic PF 1052 is selective for neutrophil migration over macrophage migration in zebrafish larvae. It also inhibits the migration of murine neutrophils when used at concentrations of 10 and 20 μM.References Antibiotic PF 1052 is a fungal metabolite originally isolated from Phoma.1,2 It is active against S. aureus, S. parvulus, and C. perfringens (MICs = 3.13, 0.78, and 0.39 μg/ml, respectively), among others.1 It inhibits neutrophil migration in a wound assay using zebrafish larvae expressing GFP-labeled neutrophils, reducing pseudopodia formation and inducing rounding of neutrophils.2 Antibiotic PF 1052 is selective for neutrophil migration over macrophage migration in zebrafish larvae. It also inhibits the migration of murine neutrophils when used at concentrations of 10 and 20 μM. References

SKF 100398, also known as d(CH2)5Tyr(Et)VAVP, is a particular analog of arginine vasopressin (AVP). It acts as a specific antagonist, specifically targeting the antidiuretic effect caused by both exogenous and endogenous AVP.

UPF 1069 is a specific PARP2 inhibitor ( IC50: 0.3 μM). It is ~27-fold selective against PARP1.

Sulfo-ara-F-NMN is an analogue of nicotinamide mononucleotide (NMN) with cellular permeability. Sulfo-ara-F-NMN was selective to activate SARM1 and inhibited CD38 with an IC50 of about 10 μM. Activation by Sulfo-ara-F-NMN to Z-48 or NMN, which has a higher cyclase activity, causes conformational changes in SARM1, resulting in cADPR production, NAD depletion, and non-apoptotic cell death.

Antifungalagent 109 (compound F) is a spirorings [thiazolidinone] compound with antifungal properties, exhibiting inhibition zones of 10-17 mm.

MLS-0053105, a chloromaleimide, functions as a selective inhibitor of BFL-1, exhibiting an IC50 of 0.4 µM against Bfl-1 F-Bid. Its inhibitory potency is over tenfold lower for Bcl-W, Bcl-2, and Bcl-XL, and it shows no activity against Bcl-B and Mcl-1.

Imarikiren (also known as TAK-272) is a potent, highly selective, orally bioavailable direct renin inhibitor primarily used for treating diabetic nephropathy. In hPRA assays, TAK-272 exhibits strong inhibitory activity against human renin (IC50 = 2.1 nM) and demonstrates excellent selectivity over other aspartic proteases such as pepsin (IC50 > 10 μM) and cathepsin D (IC50 > 10 μM). In rats, TAK-272 shows significantly improved pharmacokinetic properties (F = 25.2%) and, upon oral administration (3 and 10 mg kg), exhibits a dose-dependent, potent, and sustained antihypertensive effect. Currently, TAK-272 HCl is undergoing human clinical trials.